文献速递膀胱癌与上尿路尿路上皮癌

膀胱内吉西他滨/多西他赛与卡介苗在初治非肌层浸润性膀胱癌中的生活质量和成本效果比较

Quality of life and cost-effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG-naïve non-muscle-invasive bladder cancer.
PubMed 文献 · BJU Int · 2025-12-23

这项前瞻性按方案分析比较了吉西他滨/多西他赛(Gem/Doce)与标准卡介苗(BCG)在中间/高危非肌层浸润性膀胱癌中的生活质量和成本效果。

要点

  • Gem/Doce较BCG显著提高1年无复发生存率(94.74% vs 75%,HR 0.44,P=0.02)。
  • Gem/Doce不良事件更少(12.82% vs 34.10%,P=0.028),3级事件仅见于BCG(4.65%)。

核心结论

  • 序贯Gem/Doce相比BCG在短期生存、患者报告生活质量和安全性方面更优,且每避免复发/进展的成本具有吸引力,支持其作为资源受限环境下临床和经济可行的替代方案。

研究设计与样本

  • 前瞻性按方案分析,Gem/Doce组39例,BCG组44例,纳入中间/高危非肌层浸润性膀胱癌患者。
  • 记录生存终点(无复发生存、无进展生存)和CTCAE分级不良事件,使用EORTC QLQ-C30和QLQ-NMIBC24评估生活质量并映射至EQ-5D-5L以估算QALY。
  • 记录直接医疗成本,计算每QALY及复发/进展结局的增量成本效果比(ICER)。

主要发现

  • Gem/Doce组1年无复发生存率为94.74%,BCG组为75%(HR 0.44;P=0.02)。
  • Gem/Doce组1年无进展生存率为100.00%,BCG组为93.19%(P=0.09)。
  • Gem/Doce组不良事件发生率为12.82%,BCG组为34.10%(P=0.028);3级事件仅见于BCG组(4.65%)。
  • Gem/Doce组在6-12个月时全球健康、躯体/角色/情绪功能和性健康评分显著更高,疲劳、泌尿症状和膀胱内治疗问题更少。

关键数值与推荐

  • 1年无复发生存率:Gem/Doce 94.74% vs BCG 75%(HR 0.44;P=0.02)。
  • 1年无进展生存率:Gem/Doce 100.00% vs BCG 93.19%(P=0.09)。
  • 不良事件发生率:Gem/Doce 12.82% vs BCG 34.10%(P=0.028);3级事件仅BCG组4.65%。
  • 无复发生存延长:总体+1.38个月,高危患者+2.82个月。

临床怎么用

  • 对于中间/高危非肌层浸润性膀胱癌,序贯Gem/Doce可作为BCG的替代方案,尤其在资源受限环境中。
  • Gem/Doce在短期无复发生存、生活质量和安全性方面具有优势,且成本效果比在印度支付阈值内。

局限性

  • 本研究为按方案分析,样本量较小(Gem/Doce组39例,BCG组44例)。
  • 成本效果分析基于印度关税和支付阈值,结果外推至其他地区需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare intravesical gemcitabine/docetaxel (Gem/Doce) vs standard-of-care bacillus Calmette-Guérin (BCG) in intermediate-/high-risk non-muscle-invasive bladder cancer (NMIBC), as patient-reported physical-psychological quality of life (QoL) and cost-effectiveness estimation are pivotal to evaluate adjuvant intravesical treatments yet are rarely evaluated head-on. PATIENTS AND METHODS: In a prospective per-protocol analysis (Gem/Doce 39 patients; BCG 44 patients), survival endpoints (recurrence-free survival [RFS], progression-free survival [PFS]) and National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)-graded adverse events (AEs) were recorded. QoL was assessed at baseline, post-induction, and at 6 and 12 months using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-30-item core (EORTC QLQ-C30) and 24-item QLQ-NMIBC (QLQ-NMIBC24) and mapped to the EuroQoL five Dimensions five Levels (EQ-5D-5L) using an Indian tariff to estimate quality-adjusted life years (QALYs). Direct medical costs were recorded, and incremental cost-effectiveness ratios (ICERs) were calculated per QALY and recurrence/progression outcomes. RESULTS: Patients receiving Gem/Doce achieved higher 1-year RFS (94.74% vs 75%, hazard ratio 0.44; P = 0.02) and PFS (100.00% vs 93.19%, P = 0.09). The AEs were fewer with Gem/Doce (12.82% vs 34.10%, P = 0.028); Grade 3 events occurred only with BCG (4.65%). Gem/Doce showed significantly higher global health, physical/role/emotional functioning and sexual health scores at 6-12 months, with reduced fatigue, urinary symptoms and intravesical-treatment problems. Mean QALYs improved with Gem/Doce (0.8807 vs 0.7198), and with an ICER of ₹504 000 Indian Rupees ($6072 United States Dollars) per QALY - well within India's willingness-to-pay threshold and far below international benchmarks. Additional gains included +1.38 recurrence-free months overall and +2.82 in high-risk patients, achieved at acceptable incremental cost, indicating pragmatic cost profile against avoided recurrences and QoL gains. CONCLUSIONS: Sequential Gem/Doce delivered optimal short-term survival outcomes, favourable patient-reported QoL and safety profile, and attractive cost per avoided recurrence/progression compared with BCG, supporting its adoption as a clinically and economically viable alternative in resource-constrained NMIBC care.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Srivastava A, Trivedi S, Kumar U, et al. Quality of life and cost-effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG-naïve non-muscle-invasive bladder cancer. BJU Int. 2025. PMID: 41436847. doi:10.1111/bju.70126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。